Did SAVR outcomes suffer due to the rapid rise of TAVR? A team of researchers aimed to find out with a brand new analysis. 

Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.

Women with severe aortic stenosis and a small aortic annulus have been known to face worse outcomes after SAVR. After TAVR, however, that does not appear to be the case. 

Read our in-person coverage of the final day of ACC.22.

Learn more about the late-breaking studies presented at ACC.22 in Washington, D.C. 

Click through a wide variety of snapshots from ACC.22 in Washington, D.C. 

Self-expanding heart valves and the presence of significant PVL were both linked to a heightened risk of mitral valve infective endocarditis after TAVR. 

While the system used during the procedure has not yet gained full FDA approval, this patient was treated under a compassionate-use clearance from the agency.

Joanna Chikwe, MD, founding chair of the department of cardiac surgery at Cedars-Sinai Hospital, compares transcatheter edge-to-edge repair (TEER) to mitral valve surgery for primary mitral regurgitation.